ArticleMolecular and cellular biochemistry2026
Deciphering the anticancer potential of an entomopathogenic fungus, Cordyceps militaris in Dalton's Lymphoma transplanted murine model: a multidimensional approach involving computational methods and in vivo validation.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cordyceps militaris, a medicinal mushroom in traditional Chinese medicine, emerged as a promising source of bioactive compounds, exhibiting potent antioxidant, anti-inflammatory, anticancer, antiviral and immunomodulatory properties. Despite documenting in vitro cytotoxicity against various cancer cell lines, in vivo efficacy against Dalton's Lymphoma (DL) remains underexplored. This study investigates the anticancer efficacy of methanolic Cordyceps militaris extract (CME) against DL-bearing mice, and validate its molecular mechanism via in-silico approaches. DL-bearing Swiss albino mice treated with varying doses of CME showed significant tumor volume reduction and improved survival rates and cytotoxicity. Apoptosis induction, cell cycle progression, mitochondrial membrane potential and DNA fragmentation were analyzed using AO/EB dual staining, flow cytometry, Rhodamine-123 and comet assay, respectively. Molecular docking and dynamics simulations were performed to validate the interactions of CME's potent bioactive compound, cordycepin with anti-apoptotic target proteins, BCL-2, BCL-xL and BFL-1. CME treatment (24-96 h) led to dose- and time-dependent apoptosis supported by scanning electron microscopy, G2/M phase arrest, mitochondrial membrane depolarization and substantial DNA damage characterized by increased tail length, % tail DNA and olive tail moment in comet assay. Docking and MD simulations established strong and stable binding affinity of cordycepin to BFL-1 throughout 100ns simulation time, corroborating in vivo apoptotic outcomes. CME induces mitochondria-mediated apoptosis, DNA damage and cell cycle arrest in DL cells. This highlights the potential of C. militaris as a natural anticancer drug against lymphoma, thereby warranting further clinical validation for phytotherapeutic applications.
Indexed as
Identifiers
42183983What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.